Partner Research Programs

Funder – Novartis Pharmaceuticals Corp

Title – A Randomized, Controlled Study Evaluating the Efficacy and Safety of Ranibizumab Compared with Laser Therapy for the Treatment of Infants Born Prematurely with Retinopathy of Prematurity

Funder – NIH/NIMHD

Title – Peer Versus Adult-Led HIV Prevention for Juvenile Offenders: Effectiveness and Costs


A randomized controlled trial comparing the effectiveness and cost of different types of intervention facilitators in order to identify the most effective and sustainable way to implement the PHAT Life program within juvenile justice settings. Karen Bernstein is a collaborating physician.

Funder – Univ of Pittsburgh

Title – A Phase IIb Randomized, Double-Blind, Placebo Controlled Multi-Center Study Assess the Safety, Tolerability and Efficacy of Riociguat in Patients with SCD (STERIO-SCD)

Funder – Global Blood Therapeutics

Title – A Phase 3 Double Blind Randomized Placebo Controlled Multi Center Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Funder – Incyte

Title – A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic and Biological Activity of INCB059872 in Subjects with Sickle Cell Disease

Funder – inVentiv

Title –  A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04447943, Co-Aministered with and Wwithout Hydroxyurea

Funder – Global Blood Therapeutics

Title – A Phase 2A open Label, Multiple Dose Study Evaluate the Pharmacokinetics, Safety, Tolerability and Exploratory Treatment of GBT440 in Adolescents with SCD- Part B

Funder – Global Blood Therapeutics

Title – A Phase 2A Open Label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, tolerability and Exploratory Treatment of GBT440 in Adolescents with SCD- Part A

Funder – Chicago Community Trust

Title – Chicago Area Patient Centered Outcomes Research Network (CAPriCORN)


The Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN) is an unprecedented partnership of research institutions, clinicians, patients and patient advocates. The CAPriCORN mission is to develop, test, and implement policies and programs that will improve health care quality, health outcomes, and health equity for the richly diverse populations of the metropolitan Chicago region and beyond. Within the Chicago metropolitan area, CAPriCORN seeks to address the needs of an estimated 9.5 million residents, including groups that experience significant health inequities partly due to variable access to high-quality care.

One of 13 clinical data research networks (CDRNs) funded by the Patient-Centered Outcomes Research Institute (PCORI), CAPriCORN is able to contribute data and expertise to strengthen the capacity of PCORnet to engage in sustainable, population-wide, and patient-centered outcomes research.

Funder – US Dept of Agriculture (Natl Inst of Food & Agriculture)(fmr CREES)

Title – Rosemary as a Food Preservative: Implications for Gastrointestinal Health

Funder – NIH

Title –  Vascular- Targeted Genomic and Genetic Strategies for Acute Chest Syndrome.


Funder – NIH

Title – Non-Covalent Nrf2 Activators for the Treatment of Chronic Wounds


Chronic, non-healing wounds of the skin are serious medical complications that affect over 6.5 million Americans, especially older adults. These wounds include pressure sores, diabetic foot ulcers and venous ulcers. There are numerous surgical and dressing treatments for these wounds, but because there are over 70,000 lower-limb amputations each year arising from these wounds, it is clear that new treatments are needed. Strikingly, there are almost no pharmaceutical therapies to accelerate healing of chronic wounds. A major contributor to chronic wounds is a prolonged inflammatory state, and reducing inflammation may be a way to accelerate healing of chronic wounds. Unfortunately, many commonly used anti-inflammatory drugs hinder chronic wound healing; thus, new ways of reducing inflammation are needed. An essential factor in wound healing and an important regulator of inflammation is Nrf2, a transcription factor that induces many cytoprotective and antioxidant genes. As seen in other inflammatory disorders, activating Nrf2 could be a useful therapeutic strategy to treat chronic skin wounds. There are a number of covalent Nrf2 activators, but they are not selective for Nrf2, which is problematic because some of the off-target effects of these molecules are at proteins that hinder chronic wound healing. Thus, pharmacologic activation of Nrf2 with non-covalent small molecules will accelerate wound healing, which could lead to new therapeutics to treat chronic wounds. Our lab, in collaboration with Drs. DiPietro and Reddy labs at UIC, are using metabolism and pharmacokinetics studies, to develop high-affinity, metabolically stable, in vivo probes of Nrf2 activation for chronic wounds. These experiments are significant because they will develop novel in vivo probes of non-covalent Nrf2 activation, and they are innovative because they will open up new therapeutic strategies to treat chronic wounds.

Funder – US Dept of Health & Human Services (CDC)

Title –  SIP 14-022 Global and Territorial Health Research Collaborating Center: Illinois PRC

Title – Patient Perceptions about Sensitive Healthcare Questions

Funder – NIH

Title – Acquisition of Hyperpolarized Gas System for Lung MR Imaging

The University of Illinois at Chicago (UIC) has a large research mission focused on diagnosis and treatment of lung diseases, including lung cancer, radiation-induced lung injury, acute respiratory distress syndrome, sickle cell-linked acute chest syndrome, acute lung injury and transplant obliterative bronchiolitis. UIC also has significant expertise and facilities for developing and conducting research utilizing magnetic resonance imaging (MRI). Conventional proton (1H) MRI does not work well in the lungs due to the abundance of air. Over the past few decades hyperpolarized noble gas MRI has been shown to provide tremendous ability and insights in imaging lung disease and response to treatment. Using xenon (129Xe) gas has the added benefit that it can quantify how well gas is being exchanged in the lungs into the blood stream and tissue. We will acquire a commercial system for generation of 129Xe to catalyze the advances of our ongoing NIH-funded lung research. Additionally, this device will be a resource available not only to researchers at UIC, but also at neighboring Rush University Medical Center, Jesse Brown VA, Northwestern University, Loyola University Medical School, and University of Chicago. Existing agreements between these institutions and UIC facilitate shared usage of core instrumentation.

Funder – NIH: NCI

Title – Environmental Attributes and Weight Control: Study of Over 1.3 Million Veterans